Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies: Final appraisal document

DRAFT guidance recommends use within the Cancer Drugs Fund as an option for treating HER2-positive unresectable or metastatic breast cancer in adults after ≥2 anti-HER2 therapies, contingent on the conditions in the managed access agreement being followed.

Source:

National Institute for Health and Care Excellence